4 results about "Curative treatment" patented technology

Methods and compositions related to the treatment of autoimmune diseases using anti-CD45 antibody drug conjugates (ADCs) are disclosed. Described herein are methods and compositions for improving autohematopoietic stem cell transplantation (autoHSCT). Provided herein are methods and compositions for addressing known challenges in the field of autoHSCT, including antibodies and / or antibody drug conjugates (ADCs) that selectively target CD45 to purge autoimmune cells and enable autoHSCT as potential one-time healing treatment for patients with autoimmune diseases.

The present invention relates to the preventive or curative treatment of inflammatory diseases such as non-alcoholic fatty liver disease and inflammatory bowel diseases using Adlercreutzia bacteria.

A method and composition for treating cancer through induction of tumor cell differentiation is disclosed. Cancer cells are converted into terminally differentiated, non-proliferating cell types using specific differentiation-inducing agents, including thyroid hormone analogs such as T2 and RT3. The approach avoids the cytotoxic effects and side effects associated with conventional chemotherapy while potentially providing curative treatment. Pharmaceutical compositions include topical formulations for skin cancer treatment and various delivery systems for systemic administration. In vitro screening methods for identifying differentiation-inducing agents are also provided.

This disclosure relates to a method for treating prostate-specific membrane antigen (PSMA)-positive oligometastatic prostate cancer (OMPC) that has progressed after curative treatment for the primary tumor, comprising a therapeutically effective amount of a PSMA-binding radioligand therapy (RLT) agent, preferably [ 177 Lu]Lu-PSMA-617(Lutetium( 177 The present disclosure relates to a method comprising administering (Lu) bipivotide tetraxetan. Furthermore, the present disclosure relates to radioligand therapy for early prostate cancer patients to control the progression of recurrent tumors to lethal metastatic disease while maintaining quality of life by delaying treatment with androgen deprivation therapy (ADT).